HAYA Therapeutics has entered a multi-year collaboration with Eli Lilly to develop RNA-targeted therapies for obesity and metabolic disorders, with potential financial rewards up to $1 billion.

Information on the Target

HAYA Therapeutics, S.A. is a biotechnology firm based in Lausanne, Switzerland, specializing in precision RNA-guided regulatory genome targeting therapeutics aimed at treating chronic diseases. The company employs a proprietary regulatory genome discovery platform to identify tissue-, disease-, and cell-specific long non-coding RNA (lncRNA) targets with the potential to develop RNA-targeting therapies that exhibit improved efficacy and reduced toxicity compared to current treatment options. HAYA's lead therapeutic candidate, HTX-001, is focused on addressing heart failure, while the company is also advancing a pipeline of lncRNA-targeting precision therapies for various diseases.

Through a newly established multi-year collaboration with Eli Lilly and Company, HAYA seeks to leverage its advanced platform to support preclinical drug discovery efforts focused on obesity and associated metabolic conditions. This partnership aims to identify multiple RNA-based drug targets derived from the regulatory genome, aiming to develop novel therapeutics that can modify underlying disease mechanisms.

Industry Overview in Switzerland

The biotechnology landscape in Switzerland is robust, characterized by innovation and an extensive network of research institutions and companies. The country is home to a significant number of biotech firms, particularly in the fields of pharmaceuticals